Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelsey Brokamp

Nurse Practitioner, Adult Health Van Wert, OH Nurse Practitioner

NPI 1790039196 CMS profile 10489340

140 Fox Rd, Van Wert, OH 45891

Open in the dashboard

General payments

$9,165

604 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelsey Brokamp of Van Wert, OH is reported in the CMS Open Payments database as having received $9,165 across 604 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,657 97
2024 General $1,932 122
2023 General $2,347 152
2022 General $1,896 136
2021 General $1,333 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelsey Brokamp
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Kelsey Brokamp were reported at $1,657. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Kelsey Brokamp Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,333 $138 $43–$438 $132
2022 $1,896 $165 $54–$494 $149
2023 $2,347 $178 $61–$549 $160
2024 $1,932 $186 $62–$575 $164
2025 $1,657 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,300 173 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,420 112 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,056 63 payments
  4. Janssen Biotech, Inc. $661 39 payments
  5. QOL Medical, LLC $597 30 payments
  6. Pfizer Inc. $391 26 payments
  7. Celgene Corporation $365 26 payments
  8. Merck Sharp & Dohme Corporation $265 18 payments
  9. E.R. Squibb & Sons, L.L.C. $249 3 payments
  10. Daiichi Sankyo Inc. $239 14 payments
  11. Other $1,622 100 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,052 602 payments
  2. Education $112 2 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,130 84 payments
  2. RINVOQ $917 65 payments
  3. ENTYVIO $744 50 payments
  4. STELARA $581 35 payments
  5. ZEPOSIA $509 28 payments
  6. LINZESS $497 36 payments
  7. SKYRIZI $471 43 payments
  8. SIMPONI ARIA $392 29 payments
  9. SIMPONI $392 29 payments
  10. CREON $373 28 payments
  11. Other $5,488 360 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,186

Median for Nurse Practitioner: 389

Drug cost

$360,514

Median for Nurse Practitioner: $21,885

Branded share of claims

19.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucraid Sacrosidase Brand 13 $172,646
Zenpep Lipase/Protease/Amylase Brand 13 $119,520
Linzess Linaclotide Brand 31 $37,389
Pantoprazole Sodium Generic 366 $5,308
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 70 $4,236
Omeprazole Generic 277 $3,915
Mesalamine Generic 12 $3,578
Colestipol Hcl Generic 34 $2,556
Mesalamine Er Mesalamine Brand 14 $2,253
Loperamide Loperamide Hcl Brand 53 $1,536

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$42,313

Medicare's payments for the services billed

Medicare patients

356

Average age 73

Services billed

589

209 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 49%
Diabetes 41%
Chronic kidney disease 35%
Depression 31%
Atrial fibrillation 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
$249 — —
Sucraid
$189 13 —
RINVOQ
$163 — —
SKYRIZI
$107 — —
VELSIPITY
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

604 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record